Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

IMPORTANCE: Standard molecularly based strategies to predict and/or prevent oral cancer development in patients with oral premalignant lesions (OPLs) are lacking. OBJECTIVE: To test if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: William, William N., Papadimitrakopoulou, Vassiliki, Lee, J. Jack, Mao, Li, Cohen, Ezra E.W., Lin, Heather Y., Gillenwater, Ann M., Martin, Jack W., Lingen, Mark W., Boyle, Jay O., Shin, Dong M., Vigneswaran, Nadarajah, Shinn, Nancy, Heymach, John V., Wistuba, Ignacio I., Tang, Ximing, Kim, Edward S., Saintigny, Pierre, Blair, Elizabeth A., Meiller, Timothy, Gutkind, J. Silvio, Myers, Jeffrey, El-Naggar, Adel, Lippman, Scott M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771491/
https://ncbi.nlm.nih.gov/pubmed/26540028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.4364
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky